Preprint / Version 1

Deconstructing vaccine hesitancy: an interplay of knowledge, trust, and confidence across different populations

##article.authors##

  • Sharanya Shekhar Candor International School

DOI:

https://doi.org/10.58445/rars.3312

Keywords:

vaccine, mRNA, public, perception, survey, immunology, biology, biomedical sciences, epidemiology, viral vector, live-attenuated, toxoid, recombinant, inactivated, conjugate, opinion, knowledge, uptake, awareness

Abstract

Vaccines are one of the most effective tools in preventing contagious, dangerous and deadly diseases, and immunization programs are considered amongst the most important public health achievements worldwide. They have helped in eradicating diseases such as small pox, and contributed to the elimination of diseases such as poliomyelitis, neonatal tetanus, and rubella in many regions of the world, while reducing mortality and hospitalization rates and increasing life expectancy. Vaccines have been around for more than two centuries, evolving with changing times, from live attenuated vaccines to vector vaccines, and to mRNA vaccines. However, the differences in their design and mechanism of action are often not fully understood by the general population and this lack of understanding combined with other factors can heavily influence public mistrust in vaccines and other medical treatments.

This study provides a comparative overview of the major vaccine types and their mechanisms of action. To complement this analysis, a cross-sectional survey was conducted across diverse groups to assess public knowledge, perception, and behaviour regarding vaccine safety. The findings highlight vaccine knowledge, awareness, acceptance, and perceived risks across different demographics. The insights gained aim to support improvements in public health communication strategies.

References

Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021 Feb;21(2):83–100.

Harper DM, Navarro-Alonso JA, Bosch FX, Paavonen J, Stanley M, Sasieni P, et al. Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review. Hum Vaccines Immunother. 2025 Dec 31;21(1):2497608.

Dick AW, Perencevich EN, Pogorzelska-Maziarz M, Zwanziger J, Larson EL, Stone PW. A decade of investment in infection prevention: A cost-effectiveness analysis. Am J Infect Control. 2015 Jan;43(1):4–9.

Zhou F, Shefer A, Messonnier M, Wang LY, Lopez A, Moore M, et al. Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009. 2014;133(4).

Iwasaki A, Omer SB. Why and How Vaccines Work. Cell. 2020 Oct;183(2):290–5.

Institute of Medicine (U.S.), editor. Vaccine safety forum: summaries of two workshops. Washington, D.C: National Academy Press; 1997. 1 p. (The compass series).

Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol. 2010 June;28(6):573–9.

Sanders B, Koldijk M, Schuitemaker H. Inactivated Viral Vaccines. In: Nunnally BK, Turula VE, Sitrin RD, editors. Vaccine Analysis: Strategies, Principles, and Control [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015 [cited 2025 Aug 31]. p. 45–80. Available from: http://link.springer.com/10.1007/978-3-662-45024-6_2

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79.

Nascimento IP, Leite LCC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 2012 Dec;45(12):1102–11.

Saksena R, Chernyak A, Karavanov A, Kováč P. Conjugating Low Molecular Mass Carbohydrates to Proteins 1. Monitoring the Progress of Conjugation. In: Methods in Enzymology [Internet]. Elsevier; 2003 [cited 2025 Sept 29]. p. 125–39. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0076687903010103

Gupta S, Pellett S. Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines. Toxins. 2023 Sept 8;15(9):563.

Slomka S, Zieba P, Rosiak O, Piekarska A. Comparison of Post-Vaccination Response between mRNA and Vector Vaccines against SARS-CoV-2 in Terms of Humoral Response after Six Months of Observation. Vaccines. 2023 Oct 23;11(10):1625.

Okuyama R. mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions. Vaccines. 2023 Nov 21;11(12):1737.

Ghattas M, Dwivedi G, Lavertu M, Alameh MG. Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities. Vaccines. 2021 Dec 16;9(12):1490.

Rappuoli R, De Gregorio E, Costantino P. On the mechanisms of conjugate vaccines. Proc Natl Acad Sci. 2019 Jan 2;116(1):14–6.

Uddin MN, Roni MA. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. Vaccines. 2021 Sept 17;9(9):1033.

Mikołajczyk M, Lewandowski RA, Goncharuk AG. Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety. Vaccines. 2022 Dec 30;11(1):93.

Chatterjee B, Thakur SS. Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. Expert Rev Vaccines. 2022 Jan 2;21(1):47–67.

Offit PA. The Cutter Incident, 50 Years Later. N Engl J Med. 2005 Apr 7;352(14):1411–2.

Kurji FD, Bandyopadhyay AS, Zipursky S, Cooper LV, Gast C, Toher M, et al. Novel Oral Polio Vaccine Type 2 Use for Polio Outbreak Response: A Global Effort for a Global Health Emergency. Pathogens. 2024 Mar 23;13(4):273.

Kozak M, Hu J. The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development. Vaccines. 2023 Mar 17;11(3):695.

Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305–6.

Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019 Apr;27(4):757–72.

Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021 Apr;39(16):2190–200.

Jamous YF, Alhomoud DA. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2. Cureus [Internet]. 2023 Sept 20 [cited 2025 July 20]; Available from: https://www.cureus.com/articles/144347-the-safety-and-effectiveness-of-mrna-vaccines-against-sars-cov-2

Burgess LH, Castelein C, Rubio A, Cooper MK. COVID-19: The Vaccine Race Continues. HCA Healthc J Med [Internet]. 2021 Apr 30 [cited 2025 Aug 9];2(2). Available from: https://scholarlycommons.hcahealthcare.com/hcahealthcarejournal/vol2/iss2/2

Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines. 2021 May 6;9(5):467.

Di Fusco M, Lin J, Vaghela S, Lingohr-Smith M, Nguyen JL, Scassellati Sforzolini T, et al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022 Apr 3;21(4):435–51.

Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest. 2021 May 17;131(10):e149335.

Le Vu S, Bertrand M, Semenzato L, Jabagi MJ, Botton J, Drouin J, et al. Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis. Nat Commun. 2024 Sept 5;15(1):7745.

Fan M, Lai FTT, Cheng FWT, Tsie NTY, Li X, Wan EYF, et al. Risk of carditis after three doses of vaccination with mRNA (BNT162b2) or inactivated (CoronaVac) covid-19 vaccination: a self-controlled cases series and a case–control study. Lancet Reg Health - West Pac. 2023 June;35:100745.

Ali GGMdN, Rahman MdM, Hossain MdA, Rahman MdS, Paul KC, Thill JC, et al. Public Perceptions of COVID-19 Vaccines: Policy Implications from US Spatiotemporal Sentiment Analytics. Healthcare. 2021 Aug 27;9(9):1110.

Lazarus JV, Wyka K, White TM, Picchio CA, Rabin K, Ratzan SC, et al. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat Commun. 2022 July 1;13(1):3801.

Xu J, Wu Z, Wass L, Larson HJ, Lin L. Mapping global public perspectives on mRNA vaccines and therapeutics. Npj Vaccines. 2024 Nov 14;9(1):218.

Nathanson N, Kew OM. From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed. Am J Epidemiol. 2010 Dec 1;172(11):1213–29.

John TJ, Vashishtha VM. Eradicating poliomyelitis: India’s journey from hyperendemic to polio-free status.

Hopkins KL, Underwood T, Iddrisu I, Woldemeskel H, Bon HB, Brouwers S, et al. Community-Based Approaches to Increase COVID-19 Vaccine Uptake and Demand: Lessons Learned from Four UNICEF-Supported Interventions. Vaccines. 2023 June 30;11(7):1180.

Ittefaq M, Vu HT, Zain A, Ramazan T, Kreps GL. Analysis of public opinion polls about COVID-19 vaccines: Theoretical and policy implications for vaccine communication and campaigns to address vaccine hesitancy. Hum Vaccines Immunother. 2024 Dec 31;20(1):2437921.

Downloads

Posted

2025-10-24

Categories